Sign up to save your data!
Some tips to help get started:
Processing...
There are 397 active trials for advanced/metastatic other solid tumor. Click on a trial to see more information. Note that this list also includes some trials that are only for specific cancer types like lung cancer. To see trials customized to a patient, please select a patient above.
397 trials meet filter criteria.
Sort by:
HealthScout AI summary: The trial involves adults with advanced or metastatic non-small cell lung, colorectal, or pancreatic cancers harboring KRAS G12D mutations who have not responded to standard therapy, assessing the safety and efficacy of AZD0022, a KRASG12D inhibitor, as monotherapy and in combination with the EGFR-targeting antibody Cetuximab.
ClinicalTrials.gov ID: NCT06599502
HealthScout AI summary: This trial involves adult HLA-A*11:01-positive patients with advanced solid tumors harboring the KRAS G12V mutation, such as non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma, who have progressed on prior therapies; it evaluates AFNT-211, an investigational autologous CD4+ and CD8+ T cell therapy engineered to express a KRAS G12V-specific TCR, aiming to enhance T cell activation and persistence.
ClinicalTrials.gov ID: NCT06105021
HealthScout AI summary: The trial involves patients aged 18 or older with advanced malignancies such as malignant melanoma, head and neck squamous cell carcinoma, non-small cell lung cancer, triple negative breast cancer, and classical Hodgkin lymphoma, who have progressed after standard treatments. It evaluates the safety and tolerability of CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, intended to block the PD-1/PD-L1 interaction and enhance anti-tumor activity even in checkpoint inhibitor-resistant cancers.
ClinicalTrials.gov ID: NCT06150664
HealthScout AI summary: The trial involves patients with locally advanced or metastatic mesothelin-expressing cancers, including ovarian cancer and NSCLC, who receive ZW171, a bispecific antibody targeting mesothelin and CD3ε to facilitate T cell-mediated cancer cell killing.
ClinicalTrials.gov ID: NCT06523803
HealthScout AI summary: This trial targets patients with advanced solid tumors, including specific subtypes like HER2-positive and certain KRAS mutant cancers, and evaluates the safety and efficacy of BBO-10203, a novel PI3Kα:RAS interaction inhibitor, administered alone or with trastuzumab. Eligible patients need to have measurable disease, an ECOG status of 0-1, and prior progression on standard treatments.
ClinicalTrials.gov ID: NCT06625775
HealthScout AI summary: The trial is evaluating PT199, an anti-CD73 monoclonal antibody, alone and in combination with the PD-1 inhibitor Tislelizumab, in adult patients with advanced solid tumors, including NSCLC and pancreatic ductal adenocarcinoma, who have progressed after standard therapies.
ClinicalTrials.gov ID: NCT05431270
HealthScout AI summary: The trial evaluates LY4050784, an investigational selective SMARCA2/BRM inhibitor, for patients with advanced or metastatic solid tumors exhibiting SMARCA4/BRG1 alterations, particularly focusing on those whose standard treatments were inadequate or unavailable, including a subset with non-small cell lung cancer.
ClinicalTrials.gov ID: NCT06561685
HealthScout AI summary: This trial investigates the safety and dosing of combined intrathecal and intravenous nivolumab, a PD-1 targeting monoclonal antibody, in adult patients with leptomeningeal disease from melanoma or non-small cell lung cancer, requiring an ECOG performance status of ≤ 2.
ClinicalTrials.gov ID: NCT03025256
HealthScout AI summary: The trial investigates the safety and initial efficacy of the investigational pan-KRAS inhibitor LY4066434, targeting KRAS mutations including G12C, G12D, G12V, G12A, G12S, and G13D, in patients with locally advanced or metastatic solid tumors, and includes treatment as monotherapy or in combination with agents like nab-paclitaxel, leucovorin, and 5-fluorouracil. Eligible participants must have measurable disease with an ECOG performance status of ≤1.
ClinicalTrials.gov ID: NCT06607185
HealthScout AI summary: This trial targets patients with advanced solid tumors harboring the KRAS G12D mutation, focusing on LY3962673, an oral small molecule inhibitor selective for KRAS G12D, as both a monotherapy and in combination with chemotherapy agents like nab-paclitaxel and leucovorin. Eligible participants must have locally advanced or metastatic disease, a performance status of ≤ 1, have previously undergone chemotherapy, and must not have active CNS metastases.
ClinicalTrials.gov ID: NCT06586515
